Compare Cadence Design Systems Inc (CDNS) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs Citius Pharmaceuticals Inc — how do they compare? Cadence Design Systems Inc trades at $371.64 (market cap $104.24B), while Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M). The key difference: Cadence Design Systems Inc is far larger — about 7120.2× Citius Pharmaceuticals Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CDNS | CTXR | |
|---|---|---|
Market Cap | $104.24B | $14.64M |
Sector | Technology | Health |
52-Week High | $416.39 | $1.82 |
52-Week Low | $265.66 | $0.53 |
Enterprise Value | $105.91B | $10.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $377.92, down 1.63% on the day, with strong analyst support (84% buy ratings) and a $400.25 consensus price target. The stock shows bullish technical signals with support at $373 and resistance at $385. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results expected on July 27, 2026. Revenue growth remains robust, climbing from $3.6B in 2022 to $5.3B in 2025, though profit margins have moderated slightly.
CDNS presents a compelling growth story driven by AI and semiconductor design demand, with upside to analyst targets. However, high valuation multiples (P/E 88.09, P/S 18.68) pose risks if growth slows. Key near-term catalyst is Q2 earnings; sustained execution is critical to justify premium valuation amid competitive pressures.
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
